SUPN — Patent Expiration for TROKENDI XR (US8298576)
Apr 4, 2028, 12:00:00 AM UTC
Summary
Supernus Pharmaceuticals Inc faces the patent expiration of US8298576, which pertains to its once-daily oral medication, TROKENDI XR, on April 4, 2028. This patent covers pharmaceutical compositions of topiramate, including formulations with sustained-release and optional immediate-release components, essential for managing various pathological disorders. The expiration may permit generic competition, potentially impacting Supernus's market share and revenues.
Company
SUPERNUS PHARMACEUTICALS INC (SUPN)NASDAQ — Healthcare: Manufacturing, Drug Manufacturers - Specialty & Generic: Pharmaceutical Preparations
www.supernus.comSimilar Events
Expiration of Patent US9622983 for TROKENDI XR
The patent US9622983 for TROKENDI XR, assigned to Supernus Pharmaceuticals Inc, is set to expire on November 16, 2027. TROKENDI XR is a pharmaceutical composition of topiramate designed for once-a-day oral administration, allowing for a sustained-release delivery of the active ingredient. The anticipated expiration of this patent may open the market to generics, potentially impacting Supernus Pharmaceuticals' revenue from this product significantly.
Patent ExpirationPatent Expiration for TRIKAFTA (COPACKAGED) - US12214083
The U.S. Patent US12214083, expiring on February 27, 2033, pertains to TRIKAFTA (COPACKAGED), a drug developed by Vertex Pharmaceuticals Inc. The patent covers pharmaceutical compositions aimed at treating cystic fibrosis, specifically involving solid dispersions of a key compound. The expiration of this patent may open the market to generic competitors, potentially impacting Vertex's revenue from TRIKAFTA, which has been a significant product for the company.
Patent ExpirationPatent US8415387 Expiration Date for TRIKAFTA
The patent US8415387 related to the drug TRIKAFTA, developed by Vertex Pharmaceuticals Inc, is set to expire on November 12, 2027. TRIKAFTA is a combination drug designed to treat cystic fibrosis by modulating ATP-Binding Cassette transporters. The expiration of this patent may expose the market to generic alternatives, potentially impacting Vertex's market exclusivity and revenue from the product significantly.
patent expirationPatent US8598181 Expiration for TRIKAFTA
Patent US8598181 related to Vertex Pharmaceuticals Inc's product TRIKAFTA is set to expire on May 1, 2027. This expiration could significantly impact TRIKAFTA's market exclusivity in the treatment of cystic fibrosis, potentially altering the competitive landscape for this therapy. The patent concerns compounds that modulate ATP-Binding Cassette transporters, including Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), and methods for treating diseases associated with these transporters.
Patent Expiration